Cargando…
HGG-48. ROS1 INHIBITOR ENTRECTINIB USE IN RELAPSE/REFRACTORY INFANTILE GLIOBLASTOMA WITH POSITIVE ROS1 FUSION - A CASE REPORT WITH PROMISING RESPONSE
INTRODUCTION: Infantile glioblastoma is rare with poor prognosis. Recent molecular study for infantile hemispheric high grade glioma found its association with ALK/ROS1/NTRK/MET pathway. This suggested the potential use of targeted therapy for refractory / relapse patients. CASE: A newborn presented...
Autores principales: | Ku, Dennis Tak-Loi, Shing, Matthew Ming-Kong, Chan, Godfrey Chi-Fung, Fu, Eric, Yau, Ping-Wa, Luk, Chung-Wing, Cheng, King-Fai, Ho, Wilson Wai-Shing, Ng, Ho-Keung, Po, Yin-Chung, Ling, Alvin Siu-Cheung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715712/ http://dx.doi.org/10.1093/neuonc/noaa222.328 |
Ejemplares similares
-
HGG-23. The presence ofROS1 fusions are not limited only to infantile hemispheric glioma.
por: Trubicka, Joanna, et al.
Publicado: (2022) -
HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS
por: Robinson, Giles, et al.
Publicado: (2020) -
HGG-37. A case ofETV6-NTRK3 fusion driven infantile hemispheric glioma (IHG) with acquired drug resistance against first- and second-generation NTRK-inhibitors
por: Ku, Dennis T L, et al.
Publicado: (2022) -
HGG-52. SUSTAINED RESPONSE TO CRIZOTINIB MONOTHERAPY IN AN INFANT WITH GOPC-ROS1 FUSED CONGENITAL HEMISPHERIC GLIOMA
por: Lulla, Rishi, et al.
Publicado: (2020) -
HGG-24. NTRK-rearranged infantile gliomas of suprasellar/ optic pathway origin
por: Lazow, Margot A, et al.
Publicado: (2022)